Novacyt - Asset Resilience Ratio
Novacyt (ALNOV) has an Asset Resilience Ratio of 37.69% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Novacyt total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Novacyt's Asset Resilience Ratio has changed over time. See ALNOV net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Novacyt's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Novacyt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €23.71 Million | 37.68% |
| Short-term Investments | €10.00K | 0.02% |
| Total Liquid Assets | €23.72 Million | 37.69% |
Asset Resilience Insights
- Very High Liquidity: Novacyt maintains exceptional liquid asset reserves at 37.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Novacyt Industry Peers by Asset Resilience Ratio
Compare Novacyt's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055 |
Medical Devices | 4.92% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 22.31% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
Annual Asset Resilience Ratio for Novacyt (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Novacyt.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.13% | €30.46 Million ≈ $35.61 Million |
€70.63 Million ≈ $82.58 Million |
+43.12pp |
| 2023-12-31 | 0.01% | €9.00K ≈ $10.52K |
€133.81 Million ≈ $156.44 Million |
-61.73pp |
| 2022-12-31 | 61.73% | €86.98 Million ≈ $101.69 Million |
€140.90 Million ≈ $164.73 Million |
+6.34pp |
| 2021-12-31 | 55.39% | €101.75 Million ≈ $118.96 Million |
€183.70 Million ≈ $214.76 Million |
+16.22pp |
| 2020-12-31 | 39.17% | €91.77 Million ≈ $107.29 Million |
€234.28 Million ≈ $273.89 Million |
+33.33pp |
| 2019-12-31 | 5.84% | €1.55 Million ≈ $1.81 Million |
€26.54 Million ≈ $31.03 Million |
+2.33pp |
| 2018-12-31 | 3.51% | €1.03 Million ≈ $1.20 Million |
€29.31 Million ≈ $34.27 Million |
+3.48pp |
| 2017-12-31 | 0.03% | €8.88K ≈ $10.38K |
€30.20 Million ≈ $35.31 Million |
0.00pp |
| 2016-12-31 | 0.03% | €8.52K ≈ $9.97K |
€25.95 Million ≈ $30.34 Million |
-6.77pp |
| 2015-12-31 | 6.80% | €858.99K ≈ $1.00 Million |
€12.62 Million ≈ $14.76 Million |
+6.77pp |
| 2014-12-31 | 0.04% | €7.81K ≈ $9.13K |
€20.77 Million ≈ $24.28 Million |
-31.41pp |
| 2013-12-31 | 31.45% | €837.46K ≈ $979.08K |
€2.66 Million ≈ $3.11 Million |
-10.05pp |
| 2012-12-31 | 41.50% | €1.37 Million ≈ $1.60 Million |
€3.30 Million ≈ $3.86 Million |
+38.74pp |
| 2011-12-31 | 2.76% | €34.80K ≈ $40.69K |
€1.26 Million ≈ $1.47 Million |
+2.24pp |
| 2010-12-31 | 0.53% | €10.00K ≈ $11.69K |
€1.90 Million ≈ $2.22 Million |
+0.00pp |
| 2009-12-31 | 0.52% | €10.00K ≈ $11.69K |
€1.92 Million ≈ $2.24 Million |
-14.29pp |
| 2008-12-31 | 14.81% | €244.00K ≈ $285.26K |
€1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more